Detalles de la búsqueda
1.
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
Cephalalgia
; 44(4): 3331024241232944, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38659334
2.
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data.
Headache
; 63(3): 418-428, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36942409
3.
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Headache
; 63(6): 730-742, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37313616
4.
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Lancet
; 397(10268): 51-60, 2021 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33338437
5.
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine.
Cephalalgia
; 42(10): 1005-1012, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35332807
6.
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.
Headache
; 62(9): 1164-1176, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36111429
7.
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
Cephalalgia
; 41(14): 1458-1466, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407654
8.
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
Cephalalgia
; 41(1): 6-16, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269951
9.
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
BMC Neurol
; 21(1): 126, 2021 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33740902
10.
Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
J Headache Pain
; 22(1): 141, 2021 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34819017
11.
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
Cephalalgia
; 40(5): 470-477, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31752521
12.
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
BMC Neurol
; 20(1): 25, 2020 Jan 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31952501
13.
Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
BMC Neurol
; 20(1): 90, 2020 03 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32169042
14.
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Headache
; 60(8): 1734-1742, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32799325
15.
Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache.
Headache
; 60(10): 2254-2264, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33179263
16.
Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan.
Headache
; 60(3): 576-588, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31943195
17.
Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
Cephalalgia
; 39(11): 1343-1357, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31433669
18.
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
Cephalalgia
; 39(14): 1798-1808, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707815
19.
Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine.
Cephalalgia
; 38(2): 215-224, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29022755
20.
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
Cephalalgia
; 38(6): 1026-1037, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29471679